220 related articles for article (PubMed ID: 30060470)
21. Interphase fish analysis of cell cycle genes in asbestos-treated human mesothelial cells (HMC), SV40-transformed HMC (MeT-5A) and mesothelioma cells (COLO).
Dopp E; Poser I; Papp T
Cell Mol Biol (Noisy-le-grand); 2002; 48 Online Pub():OL271-7. PubMed ID: 12643444
[TBL] [Abstract][Full Text] [Related]
22. Human mesothelioma cells and asbestos-exposed mesothelial cells are selectively resistant to amosite toxicity: a possible mechanism for tumor promotion by asbestos.
Gabrielson EW; Van der Meeren A; Reddel RR; Reddel H; Gerwin BI; Harris CC
Carcinogenesis; 1992 Aug; 13(8):1359-63. PubMed ID: 1323425
[TBL] [Abstract][Full Text] [Related]
23. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
[TBL] [Abstract][Full Text] [Related]
24. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
[TBL] [Abstract][Full Text] [Related]
25. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
Naka T; Hatanaka Y; Marukawa K; Okada H; Hatanaka KC; Sakakibara-Konishi J; Oizumi S; Hida Y; Kaga K; Mitsuhashi T; Matsuno Y
Diagn Pathol; 2016 Apr; 11():38. PubMed ID: 27091358
[TBL] [Abstract][Full Text] [Related]
26. Mesothelioma and Colorectal Cancer: Report of Four Cases with Synchronous and Metachronous Presentation.
Serio G; Pezzuto F; Fortarezza F; Marzullo A; Delfino MC; d'Amati A; Romano DE; Maniglio S; Caporusso C; Lettini T; Cavone D; Vimercati L
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269773
[TBL] [Abstract][Full Text] [Related]
27. Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos.
Ni Z; Liu Y; Keshava N; Zhou G; Whong W; Ong T
Mutat Res; 2000 Jun; 468(1):87-92. PubMed ID: 10863160
[TBL] [Abstract][Full Text] [Related]
28. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.
Carbone M; Yang H
Clin Cancer Res; 2012 Feb; 18(3):598-604. PubMed ID: 22065079
[TBL] [Abstract][Full Text] [Related]
29. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
Andujar P; Lacourt A; Brochard P; Pairon JC; Jaurand MC; Jean D
J Toxicol Environ Health B Crit Rev; 2016; 19(5-6):151-172. PubMed ID: 27705546
[TBL] [Abstract][Full Text] [Related]
30. Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma.
Carbone M; Minaai M; Takinishi Y; Pagano I; Yang H
J Transl Med; 2023 Oct; 21(1):749. PubMed ID: 37880686
[TBL] [Abstract][Full Text] [Related]
31. Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis.
Toyokuni S
Redox Rep; 2014 Jan; 19(1):1-7. PubMed ID: 24257681
[TBL] [Abstract][Full Text] [Related]
32. [The role of macrophages in asbestos-induced carcinogenesis].
Pylev LN; Vasil'eva LA; Stadnikova NM; Smirnova OV
Vopr Onkol; 2004; 50(6):678-82. PubMed ID: 15755062
[TBL] [Abstract][Full Text] [Related]
33. Consensus Report of the 2015 Weinman International Conference on Mesothelioma.
Carbone M; Kanodia S; Chao A; Miller A; Wali A; Weissman D; Adjei A; Baumann F; Boffetta P; Buck B; de Perrot M; Dogan AU; Gavett S; Gualtieri A; Hassan R; Hesdorffer M; Hirsch FR; Larson D; Mao W; Masten S; Pass HI; Peto J; Pira E; Steele I; Tsao A; Woodard GA; Yang H; Malik S
J Thorac Oncol; 2016 Aug; 11(8):1246-1262. PubMed ID: 27453164
[TBL] [Abstract][Full Text] [Related]
34. Role of microRNAs in malignant mesothelioma.
Truini A; Coco S; Alama A; Genova C; Sini C; Dal Bello MG; Barletta G; Rijavec E; Burrafato G; Boccardo F; Grossi F
Cell Mol Life Sci; 2014 Aug; 71(15):2865-78. PubMed ID: 24562347
[TBL] [Abstract][Full Text] [Related]
35. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
[TBL] [Abstract][Full Text] [Related]
36. Malignant Mesothelioma and Its Non-Asbestos Causes.
Attanoos RL; Churg A; Galateau-Salle F; Gibbs AR; Roggli VL
Arch Pathol Lab Med; 2018 Jun; 142(6):753-760. PubMed ID: 29480760
[TBL] [Abstract][Full Text] [Related]
37. BRCA1 haploinsufficiency impairs iron metabolism to promote chrysotile-induced mesothelioma via ferroptosis resistance.
Luo Y; Akatsuka S; Motooka Y; Kong Y; Zheng H; Mashimo T; Imaoka T; Toyokuni S
Cancer Sci; 2023 Apr; 114(4):1423-1436. PubMed ID: 36541514
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis of malignant pleural mesothelioma.
Jaurand MC; Fleury-Feith J
Respirology; 2005 Jan; 10(1):2-8. PubMed ID: 15691231
[TBL] [Abstract][Full Text] [Related]
39. Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosine.
Roulois D; Deshayes S; Guilly MN; Nader JS; Liddell C; Robard M; Hulin P; Ouacher A; Le Martelot V; Fonteneau JF; Grégoire M; Blanquart C; Pouliquen DL
Oncotarget; 2016 Jun; 7(23):34664-87. PubMed ID: 27129173
[TBL] [Abstract][Full Text] [Related]
40. Iron overload signature in chrysotile-induced malignant mesothelioma.
Jiang L; Akatsuka S; Nagai H; Chew SH; Ohara H; Okazaki Y; Yamashita Y; Yoshikawa Y; Yasui H; Ikuta K; Sasaki K; Kohgo Y; Hirano S; Shinohara Y; Kohyama N; Takahashi T; Toyokuni S
J Pathol; 2012 Nov; 228(3):366-77. PubMed ID: 22864872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
